Market overview
The global implantable tibial neuromodulation market is worth USD 22 mn in 2026 and is forecast to reach USD 139 mn by 2036, growing at a 20.0% CAGR. United States is the largest country market and Coin-sized implants is the largest by device segment.
| Scope | Implanted devices that stimulate the tibial nerve at the ankle to treat overactive bladder and urinary and bowel incontinence. |
|---|---|
| Industry | Healthcare |
| Value 2025 | USD 18 mn |
| Value 2026 | USD 22 mn |
| Value 2036 | USD 139 mn |
| CAGR 2026-2036 | 20.0% |
| Volume 2026 | 1,641 units |
| Volume 2036 | 11,238 units |
| Average price 2026 | USD 13,710 per unit |
| Report price | Starts from USD 1,999 |
| Published | November 2026 |
Request a free sample of this report
Implantable Tibial Neuromodulation market size and forecast, 2026-2036
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Year | Market value |
|---|---|
| 2026 | USD 22 mn |
| 2027 | USD 27 mn |
| 2028 | USD 32 mn |
| 2029 | USD 39 mn |
| 2030 | USD 47 mn |
| 2031 | USD 56 mn |
| 2032 | USD 67 mn |
| 2033 | USD 81 mn |
| 2034 | USD 97 mn |
| 2035 | USD 116 mn |
| 2036 | USD 139 mn |
Implantable Tibial Neuromodulation market segmentation
By device
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Coin-sized implants | 54.0% | 60.6% | USD 12 mn | 21.4% |
| Pulse-generator based systems | 30.0% | 24.1% | USD 6.8 mn | 17.4% |
| Accessories and programmers | 16.0% | 15.2% | USD 3.6 mn | 19.4% |
By condition
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Overactive bladder | 72.0% | 75.9% | USD 16 mn | 20.6% |
| Faecal incontinence | 20.0% | 16.4% | USD 4.5 mn | 17.6% |
| Other conditions | 8.0% | 7.8% | USD 1.8 mn | 19.6% |
By power source
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Battery-powered pulse generator | 40.0% | 34.0% | USD 9.0 mn | 18.1% |
| Rechargeable | 24.0% | 34.0% | USD 5.4 mn | 24.2% |
| Battery-free passive | 36.0% | 32.0% | USD 8.1 mn | 18.6% |
By end user
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Hospitals | 38.0% | 34.0% | USD 8.6 mn | 18.7% |
| Urology and urogynaecology clinics | 38.0% | 40.0% | USD 8.6 mn | 20.6% |
| Ambulatory surgical centres | 24.0% | 26.0% | USD 5.4 mn | 21.0% |
By treatment pathway
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| After failed drug therapy | 52.0% | 46.0% | USD 12 mn | 18.5% |
| After failed percutaneous stimulation | 26.0% | 28.0% | USD 5.8 mn | 20.9% |
| Early alternative therapy | 22.0% | 26.0% | USD 5.0 mn | 22.0% |
Top 25 countries for implantable tibial neuromodulation by revenue
Countries are ranked by revenue earned from sales in the country, not by where the product is made. The ten largest hold 97.5% of 2026 revenue and the 25 countries below together hold 99.3%.
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| # | Country | Value 2026 | Share 2026 | Value 2036 | CAGR 2026-36 |
|---|---|---|---|---|---|
| 1 | United States | USD 15 mn | 68.0% | USD 95 mn | 20.0% |
| 2 | Germany | USD 1.4 mn | 6.0% | USD 8.4 mn | 20.0% |
| 3 | United Kingdom | USD 1.1 mn | 5.0% | USD 7.0 mn | 20.0% |
| 4 | Australia | USD 0.90 mn | 4.0% | USD 5.6 mn | 20.0% |
| 5 | France | USD 0.79 mn | 3.5% | USD 4.9 mn | 20.0% |
| 6 | Italy | USD 0.68 mn | 3.0% | USD 4.2 mn | 20.0% |
| 7 | Spain | USD 0.56 mn | 2.5% | USD 3.5 mn | 20.0% |
| 8 | Netherlands | USD 0.45 mn | 2.0% | USD 2.8 mn | 20.0% |
| 9 | Canada | USD 0.45 mn | 2.0% | USD 2.8 mn | 20.0% |
| 10 | Israel | USD 0.34 mn | 1.5% | USD 2.1 mn | 20.0% |
| 11 | Japan | USD 40 thousand | 0.2% | USD 0.24 mn | 19.3% |
| 12 | Switzerland | USD 40 thousand | 0.2% | USD 0.24 mn | 19.3% |
| 13 | Belgium | USD 34 thousand | 0.1% | USD 0.20 mn | 19.2% |
| 14 | Sweden | USD 34 thousand | 0.1% | USD 0.20 mn | 19.2% |
| 15 | Denmark | USD 29 thousand | 0.1% | USD 0.17 mn | 19.0% |
| 16 | South Korea | USD 29 thousand | 0.1% | USD 0.17 mn | 19.0% |
| 17 | Austria | USD 29 thousand | 0.1% | USD 0.17 mn | 19.0% |
| 18 | China | USD 29 thousand | 0.1% | USD 0.25 mn | 24.0% |
| 19 | Brazil | USD 22 thousand | 0.1% | USD 0.17 mn | 22.2% |
| 20 | Norway | USD 22 thousand | 0.1% | USD 0.14 mn | 20.0% |
| 21 | Ireland | USD 18 thousand | 0.08% | USD 98 thousand | 18.4% |
| 22 | Finland | USD 18 thousand | 0.08% | USD 98 thousand | 18.4% |
| 23 | Poland | USD 18 thousand | 0.08% | USD 0.13 mn | 21.4% |
| 24 | Singapore | USD 18 thousand | 0.08% | USD 98 thousand | 18.4% |
| 25 | Saudi Arabia | USD 18 thousand | 0.08% | USD 0.13 mn | 21.4% |
| Rest of world | USD 0.16 mn | 0.7% | USD 1.0 mn | 20.2% |
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
Competitive landscape
Group 1: Global leaders
- Boston Scientific
Group 2: Regional and specialist players
- Valencia Technologies
- BlueWind Medical
Group 3: Emerging and niche players
- Neuspera Medical
Research methodology
Every figure on this page comes from the research framework that we apply to all of the markets we cover. The 2025 base for the implantable tibial neuromodulation market is built from the volume sold and the price that buyers pay, and is cross-checked against the size of the wider industry the market belongs to. Where a market can be sized in more than one way, the routes are compared before a figure is set.
The forecast runs year by year from the 2025 base to 2036. Growth in each year reflects demand from the industries that buy the product, adoption of new technology, pricing, regulation and replacement cycles. Volume and price are modelled together, so revenue in each year equals volume multiplied by average price. The 2026 to 2036 compound annual growth rate of 20.0% is calculated from the resulting values.
The market is divided by device, by condition, by power source, by end user, by treatment pathway. The 25 largest countries are ranked by revenue earned from sales to buyers in each country, not by where the product is made. Segment values and country values add up to the market total in every year, and every report is checked for consistency before it is published.
Companies are placed in three groups: global leaders, regional and specialist players, and emerging and niche players. The groups describe how companies compete in the market. They are not a ranking and they are not market shares.
Our analysts also carry out primary research. Customized reports add interviews with key opinion leaders, such as senior executives, technical specialists and buyers, to test the assumptions behind the numbers for the question being asked.
Frequently asked questions
How big is the implantable tibial neuromodulation market?
The global implantable tibial neuromodulation market is estimated at USD 18 mn in 2025 and USD 22 mn in 2026.
How fast will the implantable tibial neuromodulation market grow?
It is forecast to reach USD 139 mn by 2036, a compound annual growth rate of 20.0% from 2026, an increase of USD 117 mn.
Which country is the largest market for implantable tibial neuromodulation?
United States is the largest market by revenue at USD 15 mn in 2026, 68.0% of the global total. The three largest countries together hold 79.0%.
Which country is growing fastest?
Among the ten largest markets, United States is growing fastest at 20.0% a year from 2026 to 2036.
Which implantable tibial neuromodulation segment is largest?
In the by device split, Coin-sized implants is the largest segment with 54.0% of 2026 revenue.
Who are the leading implantable tibial neuromodulation companies?
Global leaders include Boston Scientific.
Need the full report?
Request a sample to see the structure, tables and country detail.
Request a free sampleRelated markets in Healthcare
- Aniridia ImplantsUSD 14 mn · 7.5% CAGR
- AI Aortic Surgery Planning ToolUSD 55 mn · 13.0% CAGR
- Colorimetric Fructosamine Assay KitUSD 57 mn · 4.8% CAGR
- At-Home Syphilis TestingUSD 58 mn · 24.0% CAGR
- Blood Bag Tube SealerUSD 58 mn · 4.5% CAGR
- Digital Colony CounterUSD 59 mn · 5.5% CAGR
- Amyotrophic Lateral Sclerosis Gene TestingUSD 62 mn · 10.5% CAGR
- Respiration Monitor BeltUSD 63 mn · 5.2% CAGR